Is Nektar Therapeutics Still A Good Bet Despite The Correction? [Seeking Alpha]
Nektar Therapeutics (NKTR)
Last nektar therapeutics earnings: 2/27 04:15 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.nektar.com/investor-relations
Company Research
Source: Seeking Alpha
Summary Nektar Therapeutics (NASDAQ: NKTR ) is a clinical-stage biotech research company that develops drugs for cancer, auto-immune diseases, and chronic pain using its PEGylation and polymer conjugate technology platforms. Earlier in Feb 2018, Nektar secured a deal with Bristol-Myers Squibb (NASDAQ: BMY ) to co-develop NKTR-214, where BMY has agreed to pay $1.85 billion in a cash plus stock deal as payment to Nektar, as a result of which Nektar has not failed to leave investors’ radar. The drugmaker has been in the news lately, as it reported its worst one day fall in history at the beginning of June, falling around 42% and losing nearly $6 billion in market value. Here we use TipRanks data to take a closer look at what Wall Street’s top analysts see in store for this volatile stock. The massive fall in the S&P 500 stock came after the American Society of Clinical Oncology ( OTC:ASCO ) 2018 data presentation reported that patients diagnosed with melanoma aren’t respo
Show less
Read more
Impact Snapshot
Event Time:
NKTR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NKTR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NKTR alerts
High impacting Nektar Therapeutics news events
Weekly update
A roundup of the hottest topics
NKTR
News
- Nektar Therapeutics Sees Something In The Data And Puts Its Drug To The Test [Seeking Alpha]Seeking Alpha
- Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue? [Yahoo! Finance]Yahoo! Finance
- Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference [Yahoo! Finance]Yahoo! Finance
- Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferencePR Newswire
- Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata [Yahoo! Finance]Yahoo! Finance
NKTR
Earnings
- 3/4/24 - Miss
NKTR
Sec Filings
- 4/17/24 - Form 8-K
- 3/19/24 - Form D
- 3/15/24 - Form SC
- NKTR's page on the SEC website